Stakheev, Dmitry <br/><br/>
The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro.  [electronic resource] 

 -  Scientific reports  03 2019 
 - 4761 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-2322 
<br/><br/><label>Standard No.: </label>10.1038/s41598-019-41182-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--pharmacology<br/>CD4-Positive T-Lymphocytes--drug effects<br/>Cell Line, Tumor<br/>Heterocyclic Compounds, 3-Ring--pharmacology<br/>Humans<br/>Immunotherapy--methods<br/>Male<br/>Middle Aged<br/>PC-3 Cells<br/>Prostatic Neoplasms--drug therapy<br/>T-Lymphocytes--cytology<br/>Tankyrases--antagonists & inhibitors<br/>Wnt Proteins--antagonists & inhibitors<br/>Wnt Signaling Pathway--drug effects<br/>beta Catenin--antagonists & inhibitors